Research programme: Zika virus-like particle vaccine - GeoVax Labs

Drug Profile

Research programme: Zika virus-like particle vaccine - GeoVax Labs

Alternative Names: GEO ZM02; GOVX-ZM01; ZIKV Envelope protein vaccine

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeoVax Labs
  • Developer GeoVax Labs; University of Georgia
  • Class Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 19 Jun 2017 GeoVax Labs receives SBIR grant from National Institutes of Health for GEO ZM02 and ZIKV Envelope protein development in Zika virus infection
  • 19 Jun 2017 GeoVax Labs plans to initiate preclinical testing and phase I trial for GEO ZM02 and ZIKV Envelope protein vaccine for Zika virus infection
  • 03 Oct 2016 Preclinical trials in Zika virus infection (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top